GlassScriptPhysician profile
Rene Resendiz
NPI 1003403122
$10,575.27
in general payments reported to CMS, 2019-2025
17 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,377 · 2022: $2,433 · 2023: $2,252 · 2024: $2,763 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,700 · Education: $65.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,700.26 |
| Education | $65.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,812.38 | 2021-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $3,308.79 | 2021-2025 | Biktarvy, Sunlenca, Yeztugo |
| Janssen Products, LP | $653.52 | 2021-2023 | Symtuza |
| Janssen Biotech, INC. | $478.40 | 2021-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $476.13 | 2023-2025 | Pifeltro, Delstrigo, Capvaxive |
| Antares Pharma, INC. | $187.12 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Theratechnologies INC. | $121.81 | 2023-2025 | Egrifta Sv, Trogarzo, Egrifta |
| Lilly USA, LLC | $116.88 | 2024 | Mounjaro |
| Amgen INC. | $115.43 | 2024 | Repatha |
| Napo Pharmaceuticals INC | $92.97 | 2023-2025 | Mytesi |
| Emd Serono, INC. | $66.62 | 2022-2023 | Serostim |
| Halozyme INC | $31.62 | 2023 | |
| Ferring Pharmaceuticals INC. | $29.45 | 2024 | Rebyota |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Organon LLC | $21.99 | 2025 | Nexplanon |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.06 | 2021 | |
| Exact Sciences Corporation | $14.62 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Resendiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.